Market Exclusive

Analyst Activity – Wedbush Initiates Coverage On Corvus Pharmaceuticals (NASDAQ:CRVS) With a Outperform

Analyst Ratings For Corvus Pharmaceuticals (NASDAQ:CRVS)

Today, Wedbush initiated coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Outperform.

There are 4 buy ratings on the stock.

The current consensus rating on Corvus Pharmaceuticals (NASDAQ:CRVS) is Buy (Score: 3.00) with a consensus target price of $21.00 per share, a potential 77.36% upside.

Some recent analyst ratings include


Recent Trading Activity for Corvus Pharmaceuticals (NASDAQ:CRVS)
Shares of Corvus Pharmaceuticals closed the previous trading session at 11.84 down -0.25 -2.07% with 16,181 shares trading hands.

Exit mobile version